Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831

PURPOSE: To assess whether trastuzumab (H) with radiotherapy (RT) increases adverse events (AEs) after breast-conserving surgery or mastectomy. PATIENTS AND METHODS: Patients with early-stage resected human epidermal growth factor receptor 2 (HER-2) –positive breast cancer (BC) were randomly assigne...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Halyard, Michele Y., Pisansky, Thomas M., Dueck, Amylou C., Suman, Vera, Pierce, Lori, Solin, Larry, Marks, Larry, Davidson, Nancy, Martino, Silvana, Kaufman, Peter, Kutteh, Leila, Dakhil, Shaker R., Perez, Edith A.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2009
Assuntos:
Original Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2690390/
https://ncbi.nlm.nih.gov/pubmed/19349549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.17.9549
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares